Watson launches first generic Lipitor
Stephen Foley is a former Associate Business Editor of The Independent, based in New York. He left in August 2012. In a decade at the paper, he covered personal finance, the UK stock market and the pharmaceuticals industry, and had also been the Business section's share tipster. Between arriving with three suitcases in Manhattan in January 2006 and his departure, he witnessed and reported on a great economic boom turning spectacularly to bust. In March 2009, he was named Business and Finance Journalist of the Year at the British Press Awards.
Thursday 01 December 2011
Watson Pharmaceuticals, the New Jersey-based drug manufacturer, did not even wait for dawn before trumpeting its first shipments yesterday of Lipitor, the cholesterol-lowering pill that became the world's biggest selling medicine.
After years of legal and scientific battles, Lipitor's creator Pfizer yesterday relinquished its stranglehold over production of the pill, as its patent on the drug in the US finally expired. And at 5.30am, Watson announced it "began shipping the product today," and called it the "largest generic product launch in US history".
That claim is certainly true, since Lipitor, the brand name for atorvastatin calcium, still had $7.8bn (£5bn) sales in the year to September, after peaking at $10.7bn last decade. Millions of Americans pop the pills to keep their cholesterol under control and to reduce the risks of heart attacks and strokes.
But as well as being the biggest generic product launch, this is also proving to be the most unusual, as Pfizer works to maintain as big a chunk of Lipitor sales as possible. For starters, it is serving as the exclusive supplier of the medicine to Watson, at least until 2016, and it has also adopted a range of novel tactics to keep another rival, India's Ranbaxy, from taking market share. Since drugs with an estimated $80bn of sales will be going off-patent in the next two years, Pfizer is being closely watched by other pharmaceuticals giants, including GlaxoSmithKline and AstraZeneca in the UK.
Pfizer has tied up a series of deals with American health insurers and pharmacy chains to supply branded Lipitor at a discount. Generic copies typically price slightly lower than the original drug for a few months after patent expiry until additional manufacturers emerge. In deals with Medco and Express Scripts, two big pharmacy benefits managers, Pfizer has agreed to match the generics' prices.
It is also subsidising the amount consumers have to contribute to the cost of the medicine, so that Americans on Lipitor are not encouraged to switch. However, Pharmacists United for Truth and Transparency says it is a "blatant attempt" to keep health insurers paying for more expensive branded drugs.
- 1 The truth about 'girl things': Three cheers for Heather Watson's honesty
- 2 Man who held up 'hire me' sign at Waterloo station returns a year later with 'I'm hiring' sign
- 5 Men behaving badly: Urinating while standing, 'manspreading' and the gendering of selfishness
Man who held up 'hire me' sign at Waterloo station returns a year later with 'I'm hiring' sign
UK weather: Snow to fall in the coming week with sub-zero temperatures to last until early February
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Iraq invasion 2003: The bloody warnings six wise men gave to Tony Blair as he prepared to launch poorly planned campaign
Ellen DeGeneres leads Johnny Depp, Gwyneth Paltrow and Paul Bettany in revealing game of Never Have I Ever
Nigel Farage: NHS might have to be replaced by private health insurance
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
French court convicts three over homophobic tweets, in case hailed as a 'significant victory' by LGBT rights campaigners
British Muslim school children suffering a backlash of abuse following Paris attacks
George Galloway condemns 'racist, Islamophobic, hypocritical rag' Charlie Hebdo at freedom of speech rally
Islamic history is full of free thinkers - but recent attempts to suppress critical thought are verging on the absurd
iJobs Money & Business
Negotiable: Recruitment Genius: A Tax Assistant is required to join a leading ...
£16000 - £25000 per annum: Recruitment Genius: This is an exciting opportunity...
£45000 - £47000 per annum + bonus + benefits: Ashdown Group: Java Developer / ...
£35000 - £38000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...